Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:blood
|
| gptkbp:affects |
adults
|
| gptkbp:associated_with |
JAK2 V617 F mutation
|
| gptkbp:can_lead_to |
hypertension
gout skin changes splenomegaly |
| gptkbp:cause |
increased red blood cell mass
|
| gptkbp:complications |
gptkb:Oncology
thrombosis hemorrhage myelofibrosis |
| gptkbp:diagnosis |
blood tests
bone marrow biopsy |
| gptkbp:first_described_by |
1905
|
| gptkbp:genetic_studies |
recommended
|
| gptkbp:historical_significance |
first cancer linked to a specific mutation
influenced cancer research led to targeted therapies |
| https://www.w3.org/2000/01/rdf-schema#label |
polycythemia vera
|
| gptkbp:influenced_by |
gptkb:exercise
hydration dietary modifications avoidance of smoking |
| gptkbp:is_common_in |
men
older adults |
| gptkbp:is_monitored_by |
regular blood tests
symptom assessment |
| gptkbp:known_as |
polycythemia rubra vera
primary polycythemia |
| gptkbp:patient_education |
importance of follow-up
managing side effects recognizing symptoms understanding treatment options |
| gptkbp:prevalence |
rare
|
| gptkbp:related_to |
chronic myeloproliferative neoplasms
|
| gptkbp:research |
ongoing
|
| gptkbp:research_focus |
quality of life
genetic factors new therapies long-term outcomes |
| gptkbp:symptoms |
dizziness
headaches itching flushing of the face |
| gptkbp:treatment |
medications
prevent complications phlebotomy low-dose aspirin reduce blood viscosity |
| gptkbp:bfsParent |
gptkb:Incyte_Biosciences
gptkb:Jakafi gptkb:Ruxolitinib |
| gptkbp:bfsLayer |
6
|